Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2025 | Targeted ATG dosing improves CMV control and immune recovery post-transplant

Haoyang Zhang • 13 Jun 2025
EHA 2025
General Anti-thymocyte globulin

In this interview, Haoyang Zhang, PhD, Chinese PLA General Hospital, Beijing, China, discusses a study exploring the impact of antithymocyte globulin (ATG) dosing on cytomegalovirus (CMV) control and immune recovery post-transplant. This video is provided courtesy of TalkMED, in collaboration with Magdalen Medical Publishing (MMP). The interview was recorded at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.

These works are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Opportunities and challenges for real-time AI decision support in transplant care 4:47
Opportunities and challenges for real-time AI decision support in transplant care
Amin Turki • 5 Sep 2025
How AI and digital innovation are transforming transplant care 4:02
How AI and digital innovation are transforming transplant care
Amin Turki • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Stem cell transplant in 2025: latest advances, improving GvHD, and key clinical trials 8:12
Stem cell transplant in 2025: latest advances, improving GvHD, and key clinical trials
Alexandra Gomez-Arteaga • 10 Sep 2025
The content of VJHemOnc is intended for healthcare professionals